Cardiff Oncology Financials
| CRDF Stock | USD 3.45 0.05 1.47% |
Cardiff |
Understanding current and past Cardiff Oncology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cardiff Oncology's financial statements are interrelated, with each one affecting the others. For example, an increase in Cardiff Oncology's assets may result in an increase in income on the income statement.
Cardiff Oncology Stock Summary
Cardiff Oncology competes with Reviva Pharmaceuticals, PDS Biotechnology, Reviva Pharmaceuticals, Cognition Therapeutics, and Transcode Therapeutics. Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US14147L1089 |
| CUSIP | 14147L108 897238309 897238408 897238606 897238200 897238101 98410V109 |
| Location | California; U.S.A |
| Business Address | 11055 Flintkote Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cardiffoncology.com |
| Phone | 858 952 7570 |
| Currency | USD - US Dollar |
Cardiff Oncology Key Financial Ratios
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.38 | ||||
| Target Price | 10.75 | ||||
| Number Of Employees | 31 | ||||
| Beta | 1.93 |
Cardiff Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cardiff Oncology's current stock value. Our valuation model uses many indicators to compare Cardiff Oncology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cardiff Oncology competition to find correlations between indicators driving Cardiff Oncology's intrinsic value. More Info.Cardiff Oncology is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Cardiff Oncology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cardiff Oncology Systematic Risk
Cardiff Oncology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cardiff Oncology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Cardiff Oncology correlated with the market. If Beta is less than 0 Cardiff Oncology generally moves in the opposite direction as compared to the market. If Cardiff Oncology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cardiff Oncology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cardiff Oncology is generally in the same direction as the market. If Beta > 1 Cardiff Oncology moves generally in the same direction as, but more than the movement of the benchmark.
About Cardiff Oncology Financials
What exactly are Cardiff Oncology Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Cardiff Oncology's income statement, its balance sheet, and the statement of cash flows. Potential Cardiff Oncology investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cardiff Oncology investors may use each financial statement separately, they are all related. The changes in Cardiff Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cardiff Oncology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Cardiff Oncology January 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cardiff Oncology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cardiff Oncology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cardiff Oncology based on widely used predictive technical indicators. In general, we focus on analyzing Cardiff Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cardiff Oncology's daily price indicators and compare them against related drivers.
| Downside Deviation | 7.48 | |||
| Information Ratio | 0.0744 | |||
| Maximum Drawdown | 70.99 | |||
| Value At Risk | (9.47) | |||
| Potential Upside | 16.51 |
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Global Correlations Find global opportunities by holding instruments from different markets |